Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Clinically, 11q23 patients had acute lymphoblastic leukemia (ALL) more often as their primary disease and a shorter latency from start of treatment for the primary disease to their t-MDS/t-AL diagnosis, except when compared with the inv(16) subgroup.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP606209.RAW3seng0NyZBtb9rwNPhntoqxlOhTEXBM51GO43WAI_g130_assertion description "[Clinically, 11q23 patients had acute lymphoblastic leukemia (ALL) more often as their primary disease and a shorter latency from start of treatment for the primary disease to their t-MDS/t-AL diagnosis, except when compared with the inv(16) subgroup.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP606209.RAW3seng0NyZBtb9rwNPhntoqxlOhTEXBM51GO43WAI_g130_provenance.
• NP873135.RAUa7umncAIzdMCoD_PAlmnuYYJNZ6_DVAHuIMBEHrw0c130_assertion description "[Clinically, 11q23 patients had acute lymphoblastic leukemia (ALL) more often as their primary disease and a shorter latency from start of treatment for the primary disease to their t-MDS/t-AL diagnosis, except when compared with the inv(16) subgroup.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP873135.RAUa7umncAIzdMCoD_PAlmnuYYJNZ6_DVAHuIMBEHrw0c130_provenance.
• NP873358.RASamkKgtDtkUeP8YM3n2xKfbmZjgQeVxU7-677TsD0i8130_assertion description "[Clinically, 11q23 patients had acute lymphoblastic leukemia (ALL) more often as their primary disease and a shorter latency from start of treatment for the primary disease to their t-MDS/t-AL diagnosis, except when compared with the inv(16) subgroup.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP873358.RASamkKgtDtkUeP8YM3n2xKfbmZjgQeVxU7-677TsD0i8130_provenance.
• NP978711.RARhrp1rF9iiUCzXWk8v51Yb-CnzEi1FAwDvwwma-xJRM130_assertion description "[Clinically, 11q23 patients had acute lymphoblastic leukemia (ALL) more often as their primary disease and a shorter latency from start of treatment for the primary disease to their t-MDS/t-AL diagnosis, except when compared with the inv(16) subgroup.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP978711.RARhrp1rF9iiUCzXWk8v51Yb-CnzEi1FAwDvwwma-xJRM130_provenance.
• assertion description "[Clinically, 11q23 patients had acute lymphoblastic leukemia (ALL) more often as their primary disease and a shorter latency from start of treatment for the primary disease to their t-MDS/t-AL diagnosis, except when compared with the inv(16) subgroup.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Clinically, 11q23 patients had acute lymphoblastic leukemia (ALL) more often as their primary disease and a shorter latency from start of treatment for the primary disease to their t-MDS/t-AL diagnosis, except when compared with the inv(16) subgroup.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Clinically, 11q23 patients had acute lymphoblastic leukemia (ALL) more often as their primary disease and a shorter latency from start of treatment for the primary disease to their t-MDS/t-AL diagnosis, except when compared with the inv(16) subgroup.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Clinically, 11q23 patients had acute lymphoblastic leukemia (ALL) more often as their primary disease and a shorter latency from start of treatment for the primary disease to their t-MDS/t-AL diagnosis, except when compared with the inv(16) subgroup.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP781376.RAgjeCZ5Z83p-PHUtlD-6cbz_CimuvkXoSwipyWGRHM4c130_assertion description "[Clinically, 11q23 patients had acute lymphoblastic leukemia (ALL) more often as their primary disease and a shorter latency from start of treatment for the primary disease to their t-MDS/t-AL diagnosis, except when compared with the inv(16) subgroup.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP781376.RAgjeCZ5Z83p-PHUtlD-6cbz_CimuvkXoSwipyWGRHM4c130_provenance.
• NP781517.RAmig1qUp1wo3e_CkldzS6FntCHCe00qX9DRB3qaQFWK4130_assertion description "[Clinically, 11q23 patients had acute lymphoblastic leukemia (ALL) more often as their primary disease and a shorter latency from start of treatment for the primary disease to their t-MDS/t-AL diagnosis, except when compared with the inv(16) subgroup.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP781517.RAmig1qUp1wo3e_CkldzS6FntCHCe00qX9DRB3qaQFWK4130_provenance.
• NP350093.RAC7x5UeFx_Vt3jJAkvsPsdO1aXCzlZC5hi2R_y9k9fu8130_assertion description "[Clinically, 11q23 patients had acute lymphoblastic leukemia (ALL) more often as their primary disease and a shorter latency from start of treatment for the primary disease to their t-MDS/t-AL diagnosis, except when compared with the inv(16) subgroup.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP350093.RAC7x5UeFx_Vt3jJAkvsPsdO1aXCzlZC5hi2R_y9k9fu8130_provenance.
• NP350091.RAbmRHG5mnORV5qxxISg4-IxbL-gzgA0iBRk5u1S8OvrM130_assertion description "[Clinically, 11q23 patients had acute lymphoblastic leukemia (ALL) more often as their primary disease and a shorter latency from start of treatment for the primary disease to their t-MDS/t-AL diagnosis, except when compared with the inv(16) subgroup.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP350091.RAbmRHG5mnORV5qxxISg4-IxbL-gzgA0iBRk5u1S8OvrM130_provenance.
• NP350099.RAW1PUfVKzEcVJZYzoEEDZ27emVcgsw9APfP1-aNXhCoo130_assertion description "[Clinically, 11q23 patients had acute lymphoblastic leukemia (ALL) more often as their primary disease and a shorter latency from start of treatment for the primary disease to their t-MDS/t-AL diagnosis, except when compared with the inv(16) subgroup.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP350099.RAW1PUfVKzEcVJZYzoEEDZ27emVcgsw9APfP1-aNXhCoo130_provenance.
• assertion description "[Clinically, 11q23 patients had acute lymphoblastic leukemia (ALL) more often as their primary disease and a shorter latency from start of treatment for the primary disease to their t-MDS/t-AL diagnosis, except when compared with the inv(16) subgroup.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP606088.RABhKoHyzvrd-Am4Kw-X3727miKrye8O5gfygpcdwnJuk130_assertion description "[Clinically, 11q23 patients had acute lymphoblastic leukemia (ALL) more often as their primary disease and a shorter latency from start of treatment for the primary disease to their t-MDS/t-AL diagnosis, except when compared with the inv(16) subgroup.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP606088.RABhKoHyzvrd-Am4Kw-X3727miKrye8O5gfygpcdwnJuk130_provenance.
• NP605930.RAvSdc5O_EIv36fHN8N5gwsoEutBC6sVXv1_uZs83RKMY130_assertion description "[Clinically, 11q23 patients had acute lymphoblastic leukemia (ALL) more often as their primary disease and a shorter latency from start of treatment for the primary disease to their t-MDS/t-AL diagnosis, except when compared with the inv(16) subgroup.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP605930.RAvSdc5O_EIv36fHN8N5gwsoEutBC6sVXv1_uZs83RKMY130_provenance.
• NP873260.RAv859ItMB4Q5b8razhgA1IuAdfjRaKK3Z1r4ghrpAXoE130_assertion description "[Clinically, 11q23 patients had acute lymphoblastic leukemia (ALL) more often as their primary disease and a shorter latency from start of treatment for the primary disease to their t-MDS/t-AL diagnosis, except when compared with the inv(16) subgroup.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP873260.RAv859ItMB4Q5b8razhgA1IuAdfjRaKK3Z1r4ghrpAXoE130_provenance.
• NP914245.RAo6Uf_E_ccuDov0PE9O0Hj6igujn2_yRRrwmsPLh5Dzs130_assertion description "[Clinically, 11q23 patients had acute lymphoblastic leukemia (ALL) more often as their primary disease and a shorter latency from start of treatment for the primary disease to their t-MDS/t-AL diagnosis, except when compared with the inv(16) subgroup.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP914245.RAo6Uf_E_ccuDov0PE9O0Hj6igujn2_yRRrwmsPLh5Dzs130_provenance.
• NP350092.RAl2vB2qLn_wRSKrth5P4aNc6lTDxqExZaQDvKpAxfMGg130_assertion description "[Clinically, 11q23 patients had acute lymphoblastic leukemia (ALL) more often as their primary disease and a shorter latency from start of treatment for the primary disease to their t-MDS/t-AL diagnosis, except when compared with the inv(16) subgroup.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP350092.RAl2vB2qLn_wRSKrth5P4aNc6lTDxqExZaQDvKpAxfMGg130_provenance.
• NP350098.RAtQ_IuAgG2MwuRKAhx9Y_DVhpT4NdiK5gs05Q5jtyV9I130_assertion description "[Clinically, 11q23 patients had acute lymphoblastic leukemia (ALL) more often as their primary disease and a shorter latency from start of treatment for the primary disease to their t-MDS/t-AL diagnosis, except when compared with the inv(16) subgroup.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP350098.RAtQ_IuAgG2MwuRKAhx9Y_DVhpT4NdiK5gs05Q5jtyV9I130_provenance.
• NP350096.RAOc-gSVx-CGWglbZtHuUXxnrh73zILfxVTUhS_Atx2jU130_assertion description "[Clinically, 11q23 patients had acute lymphoblastic leukemia (ALL) more often as their primary disease and a shorter latency from start of treatment for the primary disease to their t-MDS/t-AL diagnosis, except when compared with the inv(16) subgroup.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP350096.RAOc-gSVx-CGWglbZtHuUXxnrh73zILfxVTUhS_Atx2jU130_provenance.
• NP350097.RAMPp6b-7OMQ5vrV4bhFX-hfkmIZjtoebgHfT64mPudpc130_assertion description "[Clinically, 11q23 patients had acute lymphoblastic leukemia (ALL) more often as their primary disease and a shorter latency from start of treatment for the primary disease to their t-MDS/t-AL diagnosis, except when compared with the inv(16) subgroup.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP350097.RAMPp6b-7OMQ5vrV4bhFX-hfkmIZjtoebgHfT64mPudpc130_provenance.
• NP781620.RA-ImGcBIU7dhsYWmx1eFnADzvEk3Z5twfe2ERjEYn8Ck130_assertion description "[Clinically, 11q23 patients had acute lymphoblastic leukemia (ALL) more often as their primary disease and a shorter latency from start of treatment for the primary disease to their t-MDS/t-AL diagnosis, except when compared with the inv(16) subgroup.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP781620.RA-ImGcBIU7dhsYWmx1eFnADzvEk3Z5twfe2ERjEYn8Ck130_provenance.
• NP978469.RA3NHTSHq2SPEpSEYhrk_99Fo3Tmbcqx0cQnzlxeHGkgQ130_assertion description "[Clinically, 11q23 patients had acute lymphoblastic leukemia (ALL) more often as their primary disease and a shorter latency from start of treatment for the primary disease to their t-MDS/t-AL diagnosis, except when compared with the inv(16) subgroup.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP978469.RA3NHTSHq2SPEpSEYhrk_99Fo3Tmbcqx0cQnzlxeHGkgQ130_provenance.
• NP978607.RA0ym3WZA_DEEFnr5O3WRwYjBhALkaXMd5cjFxT0BeBP8130_assertion description "[Clinically, 11q23 patients had acute lymphoblastic leukemia (ALL) more often as their primary disease and a shorter latency from start of treatment for the primary disease to their t-MDS/t-AL diagnosis, except when compared with the inv(16) subgroup.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP978607.RA0ym3WZA_DEEFnr5O3WRwYjBhALkaXMd5cjFxT0BeBP8130_provenance.
• NP913960.RA4-NJIVe4OFTwmDqDKjHyN0MAZOWJH1prlJWbYr5gUn8130_assertion description "[Clinically, 11q23 patients had acute lymphoblastic leukemia (ALL) more often as their primary disease and a shorter latency from start of treatment for the primary disease to their t-MDS/t-AL diagnosis, except when compared with the inv(16) subgroup.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP913960.RA4-NJIVe4OFTwmDqDKjHyN0MAZOWJH1prlJWbYr5gUn8130_provenance.
• NP914126.RAwdQqsYVlbIQW45yRrXUMJJFiK2A4WbCdn5GscaMEDpk130_assertion description "[Clinically, 11q23 patients had acute lymphoblastic leukemia (ALL) more often as their primary disease and a shorter latency from start of treatment for the primary disease to their t-MDS/t-AL diagnosis, except when compared with the inv(16) subgroup.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP914126.RAwdQqsYVlbIQW45yRrXUMJJFiK2A4WbCdn5GscaMEDpk130_provenance.
• NP350090.RA7IiDydmqIPpYX4FSK0P3PF8C2i4yat-30fi356Sd_Tk130_assertion description "[Clinically, 11q23 patients had acute lymphoblastic leukemia (ALL) more often as their primary disease and a shorter latency from start of treatment for the primary disease to their t-MDS/t-AL diagnosis, except when compared with the inv(16) subgroup.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP350090.RA7IiDydmqIPpYX4FSK0P3PF8C2i4yat-30fi356Sd_Tk130_provenance.
• NP350094.RA3GB60Duj_xKXcZ1t6FqMTKU1UuITKn5tW8960dtGXvw130_assertion description "[Clinically, 11q23 patients had acute lymphoblastic leukemia (ALL) more often as their primary disease and a shorter latency from start of treatment for the primary disease to their t-MDS/t-AL diagnosis, except when compared with the inv(16) subgroup.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP350094.RA3GB60Duj_xKXcZ1t6FqMTKU1UuITKn5tW8960dtGXvw130_provenance.
• NP350095.RAxbLuNaU-1tMG2PgPG3NylQKong-lzsUohBnwzyjonTk130_assertion description "[Clinically, 11q23 patients had acute lymphoblastic leukemia (ALL) more often as their primary disease and a shorter latency from start of treatment for the primary disease to their t-MDS/t-AL diagnosis, except when compared with the inv(16) subgroup.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP350095.RAxbLuNaU-1tMG2PgPG3NylQKong-lzsUohBnwzyjonTk130_provenance.